Headlines

Bristol-Myers Squibb Company (BMY) Q4 2025 (USD): Adj. EPS 1.26 (exp. 1.23), Revenue 12.5bln (exp. 12.28bln)

Newsquawk Staff ·

  • Adj. EPS includes net impact of -0.60 due to acquired IPR&D charges and licensing income.

Guidance

  • 2026 revenue 46-47.5bln (exp. 44.16bln).
  • 2026 adj. EPS 6.05-6.35 (exp. 6.02).

What it means

Bristol-Myers Squibb's Q4 2025 results show an adjusted EPS above expectations, albeit with a negative adjustment due to IPR&D charges. The positive guidance for 2026 revenue and EPS also surpasses market expectations, suggesting strong growth prospects that could influence sentiment in the pharmaceuticals sector and broader equities market.

Sources

Related headlines